Market Sentiment Around Loss-Making CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The US$3.9m market-cap company’s loss lessened since it announced a US$19m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$17m, as it approaches breakeven. As path to profitability is the topic on CNS Pharmaceuticals' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

According to some industry analysts covering CNS Pharmaceuticals, breakeven is near. They expect the company to post a final loss in 2026, before turning a profit of US$8.9m in 2027. The company is therefore projected to breakeven around 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2027? Working backwards from analyst estimates, it turns out that they expect the company to grow -7.5% year-on-year, on average,

Given this is a high-level overview, we won’t go into details of CNS Pharmaceuticals' upcoming projects, however, take into account that typically a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. So, periods of lower growth in the upcoming years is not out of the ordinary, particularly when a company is in a period of investment.

View our latest analysis for CNS Pharmaceuticals

One thing we’d like to point out is that The company has managed its capital prudently, with debt making up 0.9% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on CNS Pharmaceuticals, so if you are interested in understanding the company at a deeper level, take a look at CNS Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of important aspects you should further examine:

1. Historical Track Record: What has CNS Pharmaceuticals' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on CNS Pharmaceuticals' board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.